SciELO - Scientific Electronic Library Online

 
vol.10 issue3The MELD system and liver transplant waiting-list mortality in developing countries: lessons learned from São Paulo, BrazilInterventional procedures for cancer pain management author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Einstein (São Paulo)

Print version ISSN 1679-4508

Einstein (São Paulo) vol.10 no.3 São Paulo July/Sept. 2012

http://dx.doi.org/10.1590/S1679-45082012000300005 

ORIGINAL ARTICLE

 

The detection of KIT mutations in acute myeloid leukemia

 

 

Luis Eduardo Silva Machado; João Renato Rebello Pinho; Roberta Sitnik; Nair Hideko Muto; Elvira Deolinda Rodrigues Pereira Velloso; Roberta Cardoso Petroni; Paulo Vidal Campregher

Hematology Service, Hospital Israelita Albert Einstein - HIAE, São Paulo (SP), Brazil

Corresponding author

 

 


ABSTRACT

OBJECTIVE: This study describes a new method used in the clinical laboratory at Hospital Israelita Albert Einstein to detect mutations in exons 8 and 17 of the KIT gene in patients with acute myeloid leukemia.
METHODS: Genomic DNA extraction was performed on 54 samples of peripheral blood or bone marrow from patients with acute myeloid leukemia. The extracted DNA was amplified by polymerase chain reaction and sequenced, and the fragments were analyzed.
RESULTS: Within the analyzed samples, we detected four mutations in exon 8, two mutations in exon 17, and mutations or a double mutation in one sample.
CONCLUSION: The tests detecting mutations in exon 8 and 17 on the KIT gene were successfully standardized. The test is now included among the routine diagnostics employed for patients at Hospital Israelita Albert Einstein clinical laboratory.

Keywords: Leukemia, myeloid, acute; Receptor protein-tyrosine kinase; Core binding factors; Gene expression


 

 

INTRODUCTION

Acute myeloid leukemia (AML) is a bone marrow malignancy characterized by the excessive proliferation of myeloid progenitor cells (blasts), which cause neutropenia, anemia, and thrombocytopenia(1). AML is mainly diagnosed using karyotypes and by determining the molecular alterations in leukemic blasts. Using these techniques, patients are classified into groups based on their risk of relapse: high, intermediate, and low. Meanwhile, patients' prognoses are classified based on their cytogenetic and molecular abnormalities: favorable, intermediate, or unfavorable, as depicted in table 1.

 

 

Currently, AML therapies are based solely on the patients' risk of relapse. Thus, patients with an intermediate or high risk of relapse receive hematopoietic stem cell transplantation therapy, while low-risk patients only receive chemotherapy treatment(2).

Cytogenetic analysis classifies patients into their prognosis groups. For example, the chromosomal aberrations t(8;21)(q22;q22) and inv(16)(p13;q22) cause the genetic rearrangements RUNX1-RUNX1T1 (AML1-ETO) and CBFB-MYH11, respectively. Patients with these alterations are classified into the group with a favorable prognosis(3).

These two chromosomal alterations are pathophysiologically related; they alter the alpha and beta subunits of the core-binding factor (CBF) protein, respectively, and therefore they are classified as CBF leukemias. However, approximately 50% of these CBF leukemia patients experience a relapse in the disease and a high mortality rate.

Thus, identifying the risk factors associated with the relapse of disease is critical for prognostic stratification and to determining the appropriate CBF leukemia treatment. In approximately 25% of patients with CBF AML, mutations in the proto-oncogene KIT are present(4,5).

Several independent studies have shown that KIT mutations are associated with an increased risk of relapse and higher mortality rates in CBF AML patients; however, the mechanisms behind this association remain unknown(4-8). Therefore, developing tests to detect KIT mutations is vital to prognostic evaluation and classification of CBF AML patients.

 

OBJECTIVE

The objective of this study is to develop a new, in-house test for KIT mutations in patients with AML using three complementary methodologies: DNA sequencing, fragment analysis, and conformation-sensitive gel electrophoresis (CSGE). After developing this method, we will test and subsequently implement this method in the clinical laboratory of Hospital Israelita Albert Einstein (HIAE).

 

METHODS

Samples

Bone marrow or whole blood samples of AML patients (n=54) who were previously analyzed in the HIAE clinical laboratory were used for the cytogenetic and molecular evaluations in this study. Among the patients studied, 23 were diagnosed with CBF leukemia.

Extraction of genomic DNA

Using commercial kits, genomic DNA was extracted according to the manufacturers' instructions: the QIAamp DNA minikits (QIAGEN, Hilden, Germany) were used for whole blood samples; the Brazol kits (LGC Biotechnology, São Paulo, Brazil) were used for bone marrow samples. The bone marrow samples were fixed in a methanol: acetic acid solution with a final elution volume of 50µL. The extracted DNA was quantified using the NanoDrop 2000 spectrophotometer (Thermo Scientific, USA) and diluted to a final concentration that ranged from 30 to 50ng/µL.

Detection of KIT gene mutations in exons 8 and 17

In CBF AML patients, there are mutations in exons 8 and 17 of the KIT gene(5); therefore, these two exons were chosen for the current study. The mutational patterns differ between the two exons; there are point mutations in exon 17 and insertions/deletions in exon 8. Thus, to detect mutations in exon 17, we used direct sequencing of the polymerase chain reaction (PCR) product, and to detect mutations in exon 8, we used PCR with labeled primers followed by capillary electrophoresis and fragment analysis. Using primer pairs previously described in the literature(5), we studied the KIT gene. The specificity analysis of these primers was performed using in silico PCR from [http://genome.ucsc.edu/cgi-bin/hgPcr?command=start]. Subsequently, a new reverse primer was designed for exon 17, thereby allowing better analysis of this region.

The initial optimizations of the PCR reactions included variations in the MgCl2 and primer concentrations, temperature gradient tests (annealing between 51 and 71.5ºC) and the addition of 4% dimethylsulfoxide (DMSO). After comparing the results, the optimal reaction conditions were selected. To detect mutations in exon 8, the following techniques were used: capillary electrophoresis, direct sequencing of the PCR product, and CSGE. A description of these processes is detailed below.

Amplification and detection of mutations in exon 17

For amplification of this region, we initially used the primers described by Boissel et al.(5), which produced a 294-bp product: c-Kit exon 17 FW 5'-TG GTGTACTGAATACTTTAAAACAAAA-3'; c-Kit exon 17 RV 5'-TGCAGGACTGTCAAGCAGAG-3'.

Subsequently, the reverse primer was replaced to generate a 435-bp product: c-Kit exon 17 reverse2 - TAGTAATGTTCAGCATACCATGCAAATT.

The PCR reaction was performed using a cocktail containing 1x PCR buffer, 1 mM MgCl2, 0.2 mM dNTPs, 0.16µM primers c-Kit 17 FW and RV, 1 U Taq polymerase, 2µL genomic DNA (with concentrations between 30 and 50ng/µL) and sterile water qsp with a total reaction volume of 25µL. The thermocycling program consisted of an initial denaturation step at 94ºC for 5 minutes, 35 cycles at 94ºC for 45 seconds, 56ºC for 45 seconds, 72ºC for 45 seconds and a final extension at 72ºC. The aliquots of the PCR product were evaluated using gel electrophoresis in 2% agarose to determine the success of the amplification.

Next, the PCR products were column purified (Illustra GFXTM DNA and Gel Purification Kit, GE Healthcare, UK) and sequenced using the BigDye® v3.1 (Applied Biosystems, USA) sequencing reaction kit, where each of the amplification primers were used at a concentration of 1.6µM to read both DNA strands. The sequencing was performed on an ABI PRISM 3500xL automated sequencer (Applied Biosystems, USA), and the sequences were analyzed using the SeqScape® Software v2.7 (Applied Biosystems, USA) with reference sequence alignment.

Amplification and detection of mutations in exon 8

For amplification of this region, we used the primers described by Boissel et al.(5), which produced a 219-bp product: c-Kit exon 8 FW 5'-GCTGAGG TTTTCCAGCACTC-3'; c-Kit exon 8 RV 5'-AATT GCAGTCCTTCCCCTCT-3'.

The PCR reaction and the thermocycling conditions used were the same as the PCR protocol for exon 17. For capillary electrophoresis analysis, the forward primer was labeled with FAM at the 5' end.

Initially, the PCR products were sequenced as described for exon 17. When potential mutations were detected in exon 8, these products were subsequently analyzed using CSGE. In the CSGE reaction, the PCR products were denatured for 5 minutes at 98ºC followed by a reannealing step to produce heteroduplex formation, where a strand without mutations was annealed to a mutated strand for 30 minutes at 65ºC. The heteroduplex was detected by identifying differential migration on a 4% agarose gel that was stained with ethidium bromide. The second strategy to detect mutations was fragment analysis using the ABI PRISM 3500xL automated sequencer (Applied Biosystems, USA) for capillary electrophoresis.

The PCR reaction was performed under the same conditions, as described above. The PCR products were diluted 30-fold in sterile water, and 1µL was used for the reaction. Next, these PCR products were added to 8.7µL of formamide and 0.3µL of the standard DNA ladder (GeneScanTM 500 LIZ®, Applied Biosystems, UK). The mixture was incubated for 3 minutes at 95ºC and was cooled on ice for 2 minutes. The samples were applied to the sequencer and analyzed using the GeneMapper v4.1 software (Applied Biosystems, USA) to verify the fragment sizes.

Sensibility

After standardization, the sensitivity of detecting mutations in each exon was verified. For this, PCR products of a sample with approximately 50% mutated cells were diluted in a wild-type sample at equivalent DNA concentrations. Subsequently, a serial dilution was performed in the ratios of 1/1, 1/2, 1/4, and 1/8 to determine the minimum percent of mutated product that could be detected.

This work was approved by the ethics and research committee of the HIAE (process 1.663/11).

 

RESULTS

Detection of mutations in exons 8 and 17

Fifty-four AML patient samples were analyzed. Of these samples, 31 (AML1) were from patients that were not characterized as CBF AML, and 23 were characterized as CBF AML (AML2) patients, 16 had the chromosomal aberrations t(8;21), and 7 patients had the chromosomal aberration inv(16).

None of the AML1 group samples had mutations in the KIT gene; the samples from this group had previously been studied for mutations in the FLT3 and NPM1 genes. In the AML2 group, direct sequencing of PCR products was analyzed; it was observed that one of these patients had a sequencing pattern that suggested a deletion and/or an insertion in exon 8 (Figure 1).

 

 

To confirm the deletion or insertion hypothesis, two tests were used: CSGE and fragment analysis. Both of these tests confirmed the presence of two products that had a deletion of four nucleotides (Figures 2 and 3) in exon 8 of the KIT gene. After this confirmation, fragment analysis was used as the sole method to detect mutations in exon 8. The sequencing of exon 17 with the primers described above revealed low-quality sequences for several important codons, i.e., codons 825, 826, and 828. Therefore, a new reverse primer was designed, which was more distal to the sites of these important codons. This primer design ensured that the regions of the gene most likely to contain mutations in codons 801-828 were separated from the sequencing primers, thus improving the quality of the sequence.

 

 

 

 

A complete analysis of the AML2 group samples revealed KIT gene mutations in seven cases. Among them, four patients had a mutation in exon 8, two patients in exon 17 (Figure 4), and one patient had mutations in both exon 8 and exon 17 (Table 2). Unfortunately, there is no information regarding the clinical outcome of these patients because this study was conducted using previously stored samples, and many of the patients did not receive follow-up care at this institution.

 

 

 

 

Sensitivity

The sensitivity tests showed that the mutations in exon 8 were detected in at least 5% of the mutated alleles using the capillary electrophoresis method. In exon 17, the sensitivity test detected up to 12.5% of the mutated alleles using Sanger sequencing.

 

DISCUSSION

Detecting KIT gene mutations is essential for the diagnostic evaluation of CBF AML patients. Previous studies have identified these mutations in approximately 25% of CBF AML patients(4,5).

While patients with CBF AML or a wild-type KIT gene have a favorable prognosis when treated with chemotherapy alone(9,10), the presence of KIT mutations in this group of patients is associated with decreased disease-free survival(11) and overall survival(7,8). This fact led to the inclusion of KIT mutation detection in the prognostic stratification of patients by the National Comprehensive Cancer Network (NCCN). At present, patients with CBF AML and mutated KIT are receiving hematopoietic stem cell transplantations during their first complete remission(12).

In the present study, the detection of exon 8 and exon 17 mutations in the KIT gene was standardized. For this purpose, primers already described in the literature were used, and new primers were designed, which allowed a better evaluation of the sequencing product. Three different techniques detected the mutations, and two of the techniques were standardized for routine laboratory use. The KIT gene mutation was detected in 7 out of 23 patients with CBF AML at the HIAE laboratory. However, additional studies during early clinical stages and with a larger number of patients are necessary to estimate the actual frequency of these mutations in the population. In accordance with the literature, all of the mutations were detected in patients from the AML2 group of CBF AML patients(13), and no mutations were found in the KIT gene in other types of AML. However, mutations were detected in either exon 8 or exon 17, and one patient showed mutations in both exons. Although archived samples were used in this study, this test allows the patients in this study to be reclassified from a low relapse risk group to a high relapse risk group, thereby improving their prognostic stratification.

As described herein(13), the mutations in exon 8 are characterized by insertions and deletions, while in exon 17, there are point mutations. Therefore, the former are detectable using fragment analysis, while the latter require detection using sequencing.

Finally, according to previous reports, the four insertions or deletions detected in exon 8 occur in multiples of three nucleotides, thereby maintaining the reading frame(14). The sensitivity of the tests (5% for fragment analysis and 12.5% for sequencing) is consistent with previous data and is suitable for diagnostic sample analyses in samples that by definition contain at least 20% neoplastic cells.

However, for KIT gene mutations to detect the minimal residual disease, assays that are more sensitive are required, such as allele-specific PCR.

Several of the patients in this study had been assessed in a previous study for mutations in their FLT3 and NPM1 genes(15). None of the patients with these mutations showed concomitant mutation in the KIT gene. The research of KIT mutations is included in the diagnosis and treatment algorithm of the NCCN, and therefore this test will be incorporated into the tests performed at the HIAE clinical laboratory. The present study emphasizes the need to incorporate new genetic marker detections into routine diagnostics to facilitate the correct prognostic stratification and the best approach to treat acute leukemia.

 

CONCLUSION

In the present study, we describe the HIAE laboratory's development and standardization of a new test to detect mutations in the KIT gene. KIT mutations were detected in seven CBF AML patients. The availability of this diagnostic test represents an advance in the treatment of CBF AML patients by providing better prognostic stratification and identifying the most appropriate treatment.

 

REFERENCES

1. Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894-907.         [ Links ]

2. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Löwenberg B, Bloomfield CD; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.         [ Links ]

3. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Childrens Leukaemia Working Parties. Blood. 1998;92(7):2322-33.         [ Links ]

4. Care RS, Valk PJ, Goodeve AC, Abu-Duhier FM, Geertsma-Kleinekoort WM, Wilson GA, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2003;121(5):775-7.         [ Links ]

5. Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A, Raffoux E, Leblanc T, Thomas X, Hermine O, Quesnel B, Baruchel A, Leverger G, Dombret H, Preudhomme C; Acute Leukemia French Association (ALFA); Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Groups. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20(6):965-70.         [ Links ]

6. Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107(9):3463-8.         [ Links ]

7. Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107(5):1791-9.         [ Links ]

8. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, Kolitz JE, Larson RA, Bloomfield CD; Cancer and Leukemia Group B. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24(24):3904-11.         [ Links ]

9. Byrd JC, Ruppert AS, Mrózek K, Carroll AJ, Edwards CG, Arthur DC, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004;22(6):1087-94.         [ Links ]

10. Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17(12):3767-75.         [ Links ]

11. Nanri T, Matsuno N, Kawakita T, Suzushima H, Kawano F, Mitsuya H, et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia. 2005;19(8):1361-6.         [ Links ]

12. Gupta V, Tallman MS, Weisdorf DJ. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood. 2011;117(8):2307-18.         [ Links ]

13. Malaise M, Steinbach D, Corbacioglu S. Clinical implications of c-Kit mutations in acute myelogenous leukemia. Cur Hematol Malign Rep. 2009;4(2):77-82.         [ Links ]

14. Gari M, Goodeve A, Wilson G, Winship P, Langabeer S, Linch D, et al. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol. 1999;105(4):894-900.         [ Links ]

15. Velloso ED, Motta CH, Furtado JB, Bacal NS, Silveira PA, Moyses CB, et al. Molecular and cytogenetic abnormalities in acute myeloid leukemia: review and case studies. Einstein. 2011;9(2 Pt1):184-9.         [ Links ]

 

 

Corresponding author:
Paulo Vidal Campregher
Avenida Albert Einstein, 627/701 - Morumbi
Zip code: 05651-901 - São Paulo (SP), Brazil
Phone: (55 11) 2151-5555
E-mail: paulo.campregher@einstein.br

Received on: April 10, 2012
Accepted on: Aug 10, 2012
Conflict of interest: none.

 

 

Study carried out at the Hematology Service of the Hospital Israelita Albert Einstein - HIAE, São Paulo (SP), Brazil.